Skip to main content
OpenTrials
Completed

NCT Number: NCT01889849

Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers

This research protocol "Comparative pharmacokinetics and pharmacodynamics of peginterferon Bacterial Intravenous Protein 48 kilodaltons (BIP48) and 40 kilodaltons (40kDa) in healthy volunteers." This is a Phase I clinical trial which will compare pharmacokinetic and pharmacodynamic parameters, and safety of two products: peginterferon alfa-2a (PEGASYS ®) and BIP48. It will be a double-blind, randomized crossover with a rest period (wash-out) of 4 weeks. The study population will be 32 healthy male volunteers to whom will be administered a single dose of 180 microgram of each product, subcutaneously. The study will have a total duration of 14 days in each treatment step. The serum concentration of PEG-interferon for both products, measured by enzyme immunoassay (EIA) and by antiviral activity of PEG-interferon, is the main variable.For this purpose 15 samples of each volunteers will be needed. Clinical and laboratory variables, useful as pharmacodynamics parameters Beta-2 microglobulin (β2M) - 2'5'oligoadenylate synthetase - oligoadenylate synthetase (OAS)- and neopterin) and safety evaluation, will be measured.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Viral Hepatitis C Blood-Borne Infections Chronic Disease Communicable Diseases Digestive System Diseases Disease Attributes Flaviviridae Infections Hepatitis Hepatitis C Hepatitis C, Chronic Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms RNA Virus Infections Virus Diseases

Age range

18 year–35 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Bio-Manguinhos/Fiocruz

Rio de Janeiro, 21040-360, Brazil

About this study

Double-blind study, ie, the volunteers and the study team will not be aware of the product administered. As the presentations of the two products are different, only the professional who will administer the injections will not be blinded, and will not have contact with volunteers or members of the study team after applying the medication.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • No history of chronic diseases;
  • Preserved oral health;
  • No history of acute illness in the last 30 days;
  • Absence of significant clinical symptoms and signs on physical examination;
  • laboratory tests within normal limits;
  • imaging tests within normal limits;
  • Seronegative tests for HIV and B and C Hepatitis; Signing the consent form;
  • Male;
  • Age between 18 and 35 years;
  • Body mass index between 19 and 26 (weight in kg / height in meters squared).

Exclusion criteria

  • Patients with hypersensitivity to Interferon alpha, Escherichia coli-derived products, polyethylene glycol (macrogol), or any constituent salts of these preparations.
  • Individuals treated with some type of interferon at any time, prior to the present research.
  • History of chronic diseases such as autoimmune diseases, liver failure, decompensated cirrhosis, heart disease, renal failure, diabetes mellitus, thyroid diseases, hemoglobinopathies, cytopenias, history of psychiatric disease, retinopathy, optic neuritis.
  • History of acute viral disease in the last 30 days;
  • Current use of medications that alter immunity: corticosteroids, immunosuppressants;
  • History of known allergy to drugs, including interferon or to any component of the product (at the discretion of the investigator);
  • Having undergone surgery during the 6 months prior to study entry; Had donated blood three months prior to study entry;
  • History of alcoholism or current use of alcohol;
  • Use of other illicit drugs in the past 6 months;
  • Participation in a clinical study with previous therapeutic intervention in the year prior to inclusion.

Treatment and study plan

BIP 48

Drug

Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.

Other names: Peginterferon alfa 2b 48kDA

Pegasys

Drug

Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.

Other names: Peginterferon alfa 2a 40kDA

Primary outcomes

  1. Safety Assessment

    Time frame: 14 days + least 4 weeks (rest period between each administration) + 14 days

    Evaluation of safety will be estimated by the analysis of clinical chemistry and hematology (CBC and transaminase) prior to study initiation and at 24, 48, 72, 96, 120, 168 and 336 hours after administration of peginterferon alpha, in each treatment period.

Sponsors and collaborators

Lead sponsor

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

Other

Registry information

Official study title

Comparative Pharmacokinetics and Pharmacodynamics, and Safety of Two Products Containing Recombinant Human Interferon Alpha-2 Conjugated to Polyethylene Glycol in Healthy Volunteers - Phase 1.

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jul 1, 2013
Registry last updated
Jul 1, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.